TABLE 1.
Characteristics of MCI Subjects at Baseline, 6, and 12 Months (N = 286)
| Baseline | 6 mo Follow-up | 12 mo Follow-up | “Clinically Significant” Change (n) | |
|---|---|---|---|---|
| BMI (kg body weight/m2 height) | 26.0 (4.0) | 26.1 (4.2) | 26.0 (4.0) | — |
| MMSE (range: 0 to 30) | 26.9 (1.8) | 26.5 (2.6) | 26.6 (2.5) | 70 |
| ADAS-Cog (range: 0 to 70)* | 9.5 (3.7) | 14.5 (3.2) | 14.9 (3.6) | 54 |
| CDR Box Score (range: 0 to 18)* | 1.6 (0.9) | 1.8 (1.1) | 1.9 (1.2) | 86 |
| Global composite (Z-score, −1 to +1) | −0.97 (0.6) | −0.89 (0.68) | −0.91 (0.71) | — |
| Diagnostic progression from MCI to AD | — | n=15 | n=30 | 54 |
Clinically significant change was assessed by ADNI clinicians for MMSE, ADAS-cog, CDR scores (yes or no). Data presented represents the number of subjects deemed to have significant change in these tests or progressing to a diagnosis of AD.
*
Reverse scored: less impaired to more impaired performance, otherwise high scores indicate better performance.
AD indicates Alzheimer disease; ADAS-cog, Alzheimer’s Disease Assessment Scale-cognitive subscale; ADNI, Alzheimer’s Disease Neuroimaging Initiative; BMI, body mass index; CDR, clinical dementia rating; MCI, mild cognitive impairment; MMSE, Mini-Mental Status Examination.